Your search returned 10 results.

Results
	1.	Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). [electronic resource] by Cardozo, Linda Amarenco, Gerard Pushkar, Dmitry Mikulas, Jura Drogendijk, Ted Wright, Mark Compion, Gerhard Producer: 20130604 In: BJU international vol. 111 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Validation of the Patient Perception of Intensity of Urgency Scale in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. [electronic resource] by Mathias, Susan D Crosby, Ross D Nazir, Jameel Klaver, Monique Drogendijk, Ted Hakimi, Zalmai Odeyemi, Isaac A Producer: 20150420 In: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. [electronic resource] by Drake, Marcus J Chapple, Christopher Sokol, Roman Oelke, Matthias Traudtner, Klaudia Klaver, Monique Drogendijk, Ted Van Kerrebroeck, Philip Producer: 20151217 In: European urology vol. 67 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. [electronic resource] by Chapple, Christopher R Kaplan, Steven A Mitcheson, David Klecka, Jiri Cummings, Jana Drogendijk, Ted Dorrepaal, Caroline Martin, Nancy Producer: 20130708 In: European urology vol. 63 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. [electronic resource] by Cardozo, Linda Hessdörfer, Elke Milani, Rodolfo Arañó, Pedro Dewilde, Luc Slack, Mark Drogendijk, Ted Wright, Mark Bolodeoku, John Producer: 20081231 In: BJU international vol. 102 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. [electronic resource] by van Kerrebroeck, Philip Chapple, Christopher Drogendijk, Ted Klaver, Monique Sokol, Roman Speakman, Mark Traudtner, Klaudia Drake, Marcus J Producer: 20140630 In: European urology vol. 64 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	7.	Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms. [electronic resource] by Chapple, Christopher R Drake, Marcus J Van Kerrebroeck, Philip Cardozo, Linda Drogendijk, Ted Klaver, Monique Van Charldorp, Karin Hakimi, Zalmai Compion, Gerhard Producer: 20140530 In: BJU international vol. 113 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	8.	Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. [electronic resource] by Khullar, Vik Amarenco, Gerard Angulo, Javier C Cambronero, Javier Høye, Kjetil Milsom, Ian Radziszewski, Piotr Rechberger, Tomasz Boerrigter, Peter Drogendijk, Ted Wooning, Marianne Chapple, Christopher Producer: 20130708 In: European urology vol. 63 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	9.	A phase II dose-ranging study of mirabegron in patients with overactive bladder. [electronic resource] by Chapple, Christopher R Dvorak, Vladimir Radziszewski, Pjotr Van Kerrebroeck, Philip Wyndaele, Jean Jacques Bosman, Brigitte Boerrigter, Peter Drogendijk, Ted Ridder, Arwin Van Der Putten-Slob, Ingrid Yamaguchi, Osamu Producer: 20140528 In: International urogynecology journal vol. 24 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	10.	Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder. [electronic resource] by Eltink, Charlotte Lee, Jennifer Schaddelee, Marloes Zhang, Wenhui Kerbusch, Virginie Meijer, John van Marle, Sjoerd Grunenberg, Nicole Kowalski, Donna Drogendijk, Ted Moy, Selina Iitsuka, Hiromi van Gelderen, Marcel Matsushima, Hiroshi Sawamoto, Taiji Producer: 20121218 In: International journal of clinical pharmacology and therapeutics vol. 50 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)